Drugs / Cabotamig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05411133 | May 2022 → Jul 2025 | cholangiocarcinoma, colorectal adenocarcinoma, digestive system neuroendocrine neoplasm, esophageal adenocarcinoma +3 | Arbele Pty Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cabotamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05411133 ↗ |
| Known as | ARB202 | “Cabotamig (ARB202), Atezolizumab” NCT05411133 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314815 ↗ |
| Target | CDH17 | “Bispecific Antibody to CDH17 and CD3” NCT05411133 ↗ |